Our top pick for
Q2 Holdings Inc is a software-application business based in the US. Q2 shares (QTWO) are listed on the NYSE and all prices are listed in US Dollars. Q2 employs 1,749 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$80.51|
|52-week range||$73.51 - $148.56|
|50-day moving average||$82.43|
|200-day moving average||$93.73|
|Wall St. target price||$121.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-1.18%|
|1 month (2021-09-27)||-7.70%|
|3 months (2021-07-27)||-22.47%|
|6 months (2021-04-27)||-24.33%|
|1 year (2020-10-26)||-14.35%|
|2 years (2019-10-25)||15.31%|
|3 years (2018-10-26)||58.20%|
|5 years (2016-10-26)||185.50%|
Valuing Q2 stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Q2's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Q2's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.9393. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Q2's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$452.9 million|
|Gross profit TTM||$175.5 million|
|Return on assets TTM||-3.46%|
|Return on equity TTM||-19.33%|
|Market capitalisation||$4.5 billion|
TTM: trailing 12 months
There are currently 3.3 million Q2 shares held short by investors – that's known as Q2's "short interest". This figure is 4.6% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Q2 shares can be evaluated.
Q2's "short interest ratio" (SIR) is the quantity of Q2 shares currently shorted divided by the average quantity of Q2 shares traded daily (recently around 396938.82211538). Q2's SIR currently stands at 8.32. In other words for every 100,000 Q2 shares traded daily on the market, roughly 8320 shares are currently held short.
However Q2's short interest can also be evaluated against the total number of Q2 shares, or, against the total number of tradable Q2 shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Q2's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Q2 shares in existence, roughly 60 shares are currently held short) or 0.0609% of the tradable shares (for every 100,000 tradable Q2 shares, roughly 61 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Q2.
Find out more about how you can short Q2 stock.
We're not expecting Q2 to pay a dividend over the next 12 months.
Over the last 12 months, Q2's shares have ranged in value from as little as $73.51 up to $148.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Q2's is 1.4989. This would suggest that Q2's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Q2 Holdings, Inc. provides cloud-based digital banking solutions to regional and community financial institutions (RCFIs) in the United States. The company offers Q2 Digital Banking and Transactions, a browser-based digital banking solution that delivers RCFI-branded digital banking capabilities; Q2mobility App, a mobile and tablet digital banking solution; Q2mobile Remote Deposit Capture, a partnered solution that allows remote check deposit capture; and Q2 Person-to-Person Payments, a partnered integrated person-to-person payments solution. It also provides Q2 Business Solutions, a digital banking solutions to commercial end users; Q2 Sentinel, a security analytics solution; Q2 Patrol, an event-driven validation product; Q2 SMART, a targeting and messaging platform; and Q2 CardSwap that allows account holders receiving newly issued cards to automatically change their payment information. In addition, the company offers Q2 Gro, a digital account opening, and digital sales and marketing platform; Q2 Biller Direct, a bill payment solution; Centrix Dispute Tracking System, an electronic transaction dispute management solution; Centrix Payments I. Q. System, an ACH file monitoring and risk reporting solution; Centrix Exact/Transaction Management System, a fraud prevention tool; and Q2 Caliper Software Development Kit.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.